跳至主要内容
临床试验/NCT00567723
NCT00567723已完成不适用

A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)

Shire189 个研究点 分布在 1 个国家目标入组 2,105 人开始时间: 2006年4月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Shire
入组人数
2,105
试验地点
189
主要终点
Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD)

研究概览

简要总结

Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Patient must have ESRD and be receiving dialysis
  • Prior treatment with Fosrenol for a minimum of 12 consecutive weeks
  • Primary payer of healthcare must be Medicare (patient must supply Medicare Claim Number)
  • Patient must be 18 years of age or older

排除标准

  • Patients that do not meet inclusion criteria

结局指标

主要结局

Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD)

时间窗: 5 years

次要结局

  • Compare the incidence of selected morbidities among three groups of patients with ESRD(5 years)

研究者

发起方
Shire
申办方类型
Industry
责任方
Sponsor

研究点 (189)

Loading locations...

相似试验